Oncogene · 2005 · 251 citations · 13 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyChemotherapyApoptosis In CancerApoptosis RegulationApoptosis ResistanceApoptotic SignalingCancer Cell SignalingCytotoxic ChemotherapyApoptotic Signaling In CancerCancer Cell ApoptosisChemotherapy-induced ApoptosisPlatinum CompoundsPlatinum-based Agents
Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.
13
Bert Vogelstein, David P. Lane, Arnold J. Levine · Nature · 2000 · 6.6K citations
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
John N. Weinstein, Timothy G. Myers, P M O'Connor et al. · Science · 1997 · 1.2K citations
Medicine, Oncology, Pharmacology +14
Disruption of p53 in human cancer cells alters the responses to therapeutic agents
Fred Bunz, Paul M. Hwang, Chris Torrance et al. · Journal of Clinical Investigation · 1999 · 1.1K citations · Full text
Medicine, Cancer Biology, Oncology +17
Pharmacological Rescue of Mutant p53 Conformation and Function
Barbara A. Foster, Heather A. Coffey, Michael J. Morin et al. · Science · 1999 · 801 citations
Medicine, Oncology, Pharmacology +13